Etretinate: Persistent Serum Levels After Long-term Therapy

Archives of Dermatology

Volumn 125, Issue 2, 1989, Pages 246-251

  Digiovanna, John J ^a,d   Zech, Loren A ^b,d   Ruddel, Mark E ^c,d   Gantt, Gail ^a,d   Peck, Gary L ^a,d  

^a Dermatology Branch   (United States)

^b Laboratory of Mathematical Biology ^*  (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETINATE;

BLOOD LEVEL; CLINICAL ARTICLE; DRUG CONCENTRATION; HUMAN; HUMAN CELL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADIPOSE TISSUE; BODY WEIGHT; ETRETINATE; HALF-LIFE; HUMAN; PSORIASIS; TIME FACTORS;

EID: 85047691549     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.125.2.246     Document Type: Article

References (20)

1. Paravicini U, Stockel K, MacNamara PJ, et al: On metabolism and pharmacokinetics of an aromatic retinoid. Ann NY Acad Sci 1981;359:54–67.
2. Paravicini U: Pharmacokinetics and metabolism of oral aromatic retinoids, in Orfanos CE, Braun-Falco CEO, Farber EM (eds): Retinoids: Advances in Basic Research and Therapy. New York, Springer-Verlag NY Inc, 1981, pp 13–20.
3. Vahlquist A, Michaelsson G, Kober A, et al: Retinoid-binding proteins and the plasma transport of etretinate (Ro 10-9359) in man, in Orfanos CE, Braun-Falco CEO, Farber EM (eds): Retinoids: Advances in Basic Research and Therapy. New York, Springer-Verlag NY Inc, 1981, pp 109–116.
4. Brazzel RK, Colburn WA: Pharmacokinetics of the retinoids isotretinoin and etretinate: A comparative review. J Am Acad Dermatol 1982;6(pt 2):643–651.
5. Lauharanta J, Paravicini U, Kanerva L, et al: Decline of plasma concentrations of etretinate and its main metabolite after treatment. Arch Dermatol Res 1982;274:377–379.
6. DiGiovanna JJ, Zech LA, Ruddel ME, et al: Etretinate: Persistent serum levels of a potent teratogen, abstracted. J Invest Dermatol 1984;82:434A
7. Clin Res 1984;32:57A
8. Paravicini U, Busslinger A: Etretinate and isotretinoin, two retinoids with different pharmacokinetic profiles, in Cunliffe WJ, Miller AJ (eds): Retinoid Therapy: A Review of Clinical and Laboratory Research. Lancaster, England, MTP Press Ltd, 1984, pp 11–23.
9. Lucek RW, Colburn WA: Clinical pharmacokinetics of the retinoids. Clin Pharmacokinet 1985;10:38–62.
10. Lammar EJ, Chen DT, Hoar RM, et al: Retinoic acid embryopathy. N Engl J Med 1985;313:837–841.
11. Kamm JJ: Toxicology, carcinogenicity, and teratogenicity of some orally administered retinoids. J Am Acad Dermatol 1982;6(pt 2):652–659.
12. Rollman O, Vahlquist A: Retinoid concentrations in skin, serum and adipose tissue of patients treated with etretinate. Br J Dermatol 1983;109:439–447.
13. Vahlquist A, Rollman O: Further observations on the pharmacology of retinoids, in Cunliffe WJ, Miller AJ (eds): Retinoid Therapy: A Review of Clinical and Laboratory Research. Lancaster, England, MTP Press Ltd, 1984, pp 135–143.
14. McClean SW, Ruddel ME, Gross EG, et al: Liquid chromatographic assay for retinol (vitamin A) and retinol analogs in therapeutic trials. Clin Chem 1982;28:693–696.
15. Berman M, Beltz WF, Greif PC, et al: CONSAM User's Guide. Washington, DC, US Dept Health and Human Services, Public Health Service, National Institutes of Health, 1983.
16. Berman M, Weiss MF: SAAM Manual: SAAM27 Version, US Dept Health, Education, Welfare publication (NIH) 78-180, 1978.
17. Jelliffe DB: The Assessment of the Nutritional Status of the Community. Geneva, World Health Organization, 1966, pp 238–241.
18. Massarella J, Vane F, Bugge C, et al: Etretinate kinetics during chronic dosing in severe psoriasis. Clin Pharmacol Ther 1985;37:439–446.
19. Hanni R: Pharmacokinetic and metabolic pathways of systemically applied retinoids. Dermatologica 1978;157(suppl 1): 5–10.
20. DiGiovanna JJ, Gross EG, McClean SW, et al: Etretinate: Effect of milk intake on absorption. J Invest Dermatol 1984;82:636–640.